Skip to content

Market/Novel Tech

EyePoint Pharmaceuticals announce interim results from a Phase 2 EYP-1901 treatment (a tyrosine kinase inhibitor with a sustained delivery insert) for DME patients.    

EyePoint Pharmaceuticals, Inc. (NASDAQ: EYPT), based in Watertown, Massachusetts, have announced positive interim 16-week data for an ongoing Phase 2 “VERONA” clinical trial, evaluating “DURAVYU”… Read More »EyePoint Pharmaceuticals announce interim results from a Phase 2 EYP-1901 treatment (a tyrosine kinase inhibitor with a sustained delivery insert) for DME patients.    

Ocuphire Pharma Inc., has acquired Opus Genetics, aimed to advance treatments quickly for several ophthalmic indications.    

Ocuphire Pharma, Inc. (Nasdaq: OCUP), based in Farmington Hills, Michigan, USA announced the all-stock acquisition of Opus Genetics, Inc., a private ocular gene therapy company… Read More »Ocuphire Pharma Inc., has acquired Opus Genetics, aimed to advance treatments quickly for several ophthalmic indications.    

Roche supported by a real-world study with initial outcomes on faricimab at EURETINA Congress – treatment-naïve patients with nAMD and DME (VOYAGER Study).    

Delegates at the EURETINA Congress in Barcelona (Sept. 20th 2024) have heard new outcome data from a real-world study on faricimab (anti-VEGF, Vabymso), for naïve… Read More »Roche supported by a real-world study with initial outcomes on faricimab at EURETINA Congress – treatment-naïve patients with nAMD and DME (VOYAGER Study).    

HuidaGene Therapeutics presents a novel AAV9 RPE-65 treatment for Leber congenital amaurosis at EURETINA Congress in Barcelona.    

HuidaGene Therapeutics, based in Shanghai, China and Clinton, New Jersey, have  reported preliminary data on a novel gene therapy treatment for RPE-65 LCA (Leber congenital… Read More »HuidaGene Therapeutics presents a novel AAV9 RPE-65 treatment for Leber congenital amaurosis at EURETINA Congress in Barcelona.    

Merck (NYSE: MRK) and Eyebiotech Ltd (UK) completes acquisition, following a recent experimental treatment (“Restoret”) for diabetic macular edema (DME).    

Merck (NYSE: MRK) has recently announced the completion of the acquisition of Eyebiotech Limited (EyeBio), now becoming a wholly-owned subsidiary of Merck.  EyeBio was founded… Read More »Merck (NYSE: MRK) and Eyebiotech Ltd (UK) completes acquisition, following a recent experimental treatment (“Restoret”) for diabetic macular edema (DME).    

Kioro Pharmaceuticals (NASDAQ: KPRX) has announced Orphan Medicinal Product Designation for KIO-310, for the treatment of non-syndromic rod-dominant retinal dystrophies.    

Kiora Pharmaceuticals (NASDAQ: KPRX) have announced the receipt of Orphan Medicinal Product Designation from the European Medicines Agency (EMA) for the treatment of IRDs, including… Read More »Kioro Pharmaceuticals (NASDAQ: KPRX) has announced Orphan Medicinal Product Designation for KIO-310, for the treatment of non-syndromic rod-dominant retinal dystrophies.    

Genentech (Roche Group) announce that FDA has approved the introduction of Susimvo (ranibizumab injection, ocular implant) for wet age-related macular degeneration. 

Genentech, a member of the Roche Group (SIX: RO, ROG; OTCQX: RHHBY), have announced the reintroduction of “Susvimo” (ranibizumab injection) 100 mg/mL for intravitreal use… Read More »Genentech (Roche Group) announce that FDA has approved the introduction of Susimvo (ranibizumab injection, ocular implant) for wet age-related macular degeneration. 

Nanoscope Therapeutics Inc., provides a commercial update on  MCO-010 treatment of retinitis pigmentosa (RP) using optogenetic therapy. 

Nanoscope Therapeutics Inc., a company based in Bedford, Texas, has provided an update following recent regulatory discussions with the U.S. Food and Drug Administration (“FDA”)… Read More »Nanoscope Therapeutics Inc., provides a commercial update on  MCO-010 treatment of retinitis pigmentosa (RP) using optogenetic therapy.